GlassScriptPhysician profile
Alexander P Kim
NPI 1265504583
$19,828.87
in general payments reported to CMS, 2019-2025
36 companies · $4,491 in 2025
The $4,491 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,970 · 2020: $1,773 · 2021: $2,495 · 2022: $2,664 · 2023: $2,511 · 2024: $3,926 · 2025: $4,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,913.51 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,093.11 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,021.44 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $1,981.51 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,909.14 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $995.23 | 2022-2025 | |
| Madrigal Pharmaceuticals | $890.24 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $683.22 | 2019-2024 | Dificid |
| Lilly USA, LLC | $470.46 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $454.84 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $439.20 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $386.70 | 2023-2025 | Dupixent |
| Allergan, INC. | $354.87 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $322.64 | 2019-2024 | Linzess |
| Romark Laboratories, Lc | $312.29 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $296.56 | 2024-2025 | Vowst, Zenpep |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $276.89 | 2021-2025 | Renflexis, Hadlima |
| Ardelyx, INC. | $224.43 | 2025 | Ibsrela |
| Daiichi Sankyo INC. | $216.05 | 2021-2024 | Injectafer |
| Celgene Corporation | $189.80 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $189.77 | 2020-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $173.47 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $152.83 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $140.19 | 2021 | |
| Braintree Laboratories, INC. | $101.57 | 2019-2025 | Sutab, Suflave |
| Echosens North America, INC. | $84.06 | 2023 | Fibroscan |
| Alnylam Pharmaceuticals INC. | $82.16 | 2021-2024 | Givlaari |
| Phathom Pharmaceuticals, INC. | $74.69 | 2025 | Voquezna |
| Alfasigma USA, INC. | $64.02 | 2020-2022 | |
| Exact Sciences Corporation | $62.38 | 2023 | Cologuard Collection Kit |
| Shionogi INC | $53.70 | 2019-2020 | |
| Biocon Biologics INC | $42.10 | 2025 | Yesintek |
| Amgen INC. | $18.88 | 2021 | |
| Capsovision, INC. | $18.29 | 2025 | Capsocam Plus |
| Ferring Pharmaceuticals INC. | $17.90 | 2020 | |
| Amag Pharmaceuticals, INC. | $17.17 | 2021 | |
| Acacia Pharma INC | $17.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.